Nice to be reminded
Conclusion: Economically, although the net profit per square centimeter of dermal template may favor IDRT, the ancillary benefits associated with BTM in terms of reduced hospital stay, shorter surgery times, fewer follow-up visits, and lower revisionary surgery rates contribute substantially to overall cost-effectiveness. Biodegradable Temporizing Matrix use reflects more efficient resource use and potential cost savings, aligning with broader trends in healthcare emphasizing value-based and patient-centered care.
https://pubmed.ncbi.nlm.nih.gov/38556669/
The Clinicians Speak, page-845
-
- There are more pages in this discussion • 189 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
-0.030(1.15%) |
Mkt cap ! $1.780B | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.61 | $2.56 | $1.865M | 722.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2728 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.59 | 1995 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |